Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555, United States.
Chem Biol Interact. 2011 May 30;191(1-3):346-50. doi: 10.1016/j.cbi.2011.02.028. Epub 2011 Mar 3.
Aldose reductase (AKR1B1), which catalyzes the reduction of glucose to sorbitol and lipid aldehydes to lipid alcohols, has been shown to be involved in secondary diabetic complications including cataractogenesis. Rats have high levels of AKR1B1 in lenses and readily develop diabetic cataracts, whereas mice have very low levels of AKR1B1 in their lenses and are not susceptible to hyperglycemic cataracts. Studies with transgenic mice that over-express AKR1B1 indicate that it is the key protein for the development of diabetic complications including diabetic cataract. However, no such studies were performed in genetically altered AKR1B1 rats. Hence, we developed siRNA-based AKR1B1 knockdown rats (ARKO) using the AKR1B1-siRNA-pSuper vector construct. Genotyping analysis suggested that more than 90% of AKR1B1 was knocked down in the littermates. Interestingly, all the male animals were born dead and only 3 female rats survived. Furthermore, all 3 female animals were not able to give birth to F1 generation. Hence, we could not establish an AKR1B1 rat knockdown colony. However, we examined the effect of AKR1B1 knockdown on sugar-induced lens opacification in ex vivo. Our results indicate that rat lenses obtained from AKR1B1 knockdown rats were resistant to high glucose-induced lens opacification as compared to wild-type (WT) rat lenses. Biochemical analysis of lens homogenates showed that the AKR1B1 activity and sorbitol levels were significantly lower in sugar-treated AKR1B1 knockdown rat lenses as compared to WT rat lenses treated with 50mM glucose. Our results thus confirmed the significance of AKR1B1 in the mediation of sugar-induced lens opacification and indicate the use of AKR1B1 inhibitors in the prevention of cataractogenesis.
醛糖还原酶(AKR1B1)可催化葡萄糖还原为山梨醇和脂质醛转化为脂质醇,已被证明与包括白内障形成在内的二级糖尿病并发症有关。大鼠晶状体中 AKR1B1 水平较高,容易发生糖尿病性白内障,而小鼠晶状体中 AKR1B1 水平非常低,不易发生高血糖性白内障。使用过表达 AKR1B1 的转基因小鼠的研究表明,它是导致包括糖尿病性白内障在内的糖尿病并发症的关键蛋白。然而,在基因改变的 AKR1B1 大鼠中没有进行此类研究。因此,我们使用 AKR1B1-siRNA-pSuper 载体构建物开发了基于 siRNA 的 AKR1B1 敲低大鼠(ARKO)。基因分型分析表明,同窝仔鼠中超过 90%的 AKR1B1 被敲低。有趣的是,所有雄性动物均出生死亡,仅 3 只雌性大鼠存活。此外,这 3 只雌性动物均无法生育 F1 代。因此,我们无法建立 AKR1B1 大鼠敲低品系。然而,我们在离体实验中检查了 AKR1B1 敲低对糖诱导晶状体混浊的影响。我们的结果表明,与野生型(WT)大鼠晶状体相比,来自 AKR1B1 敲低大鼠的晶状体对高葡萄糖诱导的晶状体混浊具有抗性。晶状体匀浆的生化分析表明,与用 50mM 葡萄糖处理的 WT 大鼠晶状体相比,糖处理的 AKR1B1 敲低大鼠晶状体中的 AKR1B1 活性和山梨醇水平明显降低。我们的结果因此证实了 AKR1B1 在介导糖诱导的晶状体混浊中的重要性,并表明 AKR1B1 抑制剂在白内障形成预防中的应用。